Immunotherapy combo shows promise for advanced cervical cancer
Disease control
Terminated
This phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC